• Users Online: 238
  • Print this page
  • Email this page
Year : 2020  |  Volume : 7  |  Issue : 1  |  Page : 29-33

Germline BRCA2 mutation pancreatic adenocarcinoma

1 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital; School of Medicine, National Yang-Ming University, Taipei, Taiwan
2 School of Medicine, National Yang-Ming University; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Correspondence Address:
Dr. Ming-Huang Chen
Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Rd., Taipei 112
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCRP.JCRP_20_19

Rights and Permissions

Pancreatic adenocarcinoma is one of the most challenging malignancies. Its surgical resection is regarded as the only potential curative treatment. However, most patients present with advanced stages, associated with very poor prognosis. Germline BRCA1 and BRCA2 (BRCA1/2) mutations account for few advanced pancreatic adenocarcinomas and thus present as disease-specific entities. Cancers harboring BRCA1/2 mutations are relatively more chemosensitive and have exhibited survival benefits with platinum-containing combination treatments. FOLFIRINOX has been evaluated in various trials and is a well-established first-line chemotherapy for metastatic pancreatic cancer in patients with good performance status. Here, we report the case of a patient with germline BRCA2-mutation pancreatic adenocarcinoma who exhibited a good response to modified FOLFIRINOX, achieving an 18-month complete response.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded139    
    Comments [Add]    

Recommend this journal